MDAI stock jumped after Spectral AI, Inc. won $31.70M in BARDA funding, closing the NASDAQ session at $1.42 on 19 Mar 2026. Volume surged to 7,175,859 shares versus an average of 402,294, signaling heavy investor interest. The company reports earnings on 24 Mar 2026 after the close, a key catalyst that could reset sentiment. We focus on financials, the BARDA impact, trading metrics, and what to watch into the earnings print for MDAI stock.
MDAI stock: Why the $31.70M BARDA award matters
The BARDA award funds development of Spectral AI’s DeepView burn-imaging system and adds non-dilutive capital of $31.70M to existing support. This funding reduces near-term financing pressure and accelerates FDA clearance work. The contract expands the company’s role in burn triage and emergency use, which is material for commercial adoption and reimbursement discussions.
Earnings calendar and what to watch in the MDAI earnings report
Spectral AI reports results on 24 Mar 2026 after market close. Investors should watch revenue trends, guidance on FDA timing, and R&D spend tied to the BARDA program. Management comments about reimbursement pilots, burn center trials, and the expected FDA milestone will likely move the stock. Quarterly results may not be profitable yet; EPS TTM stands at -0.75 and price-to-earnings is -1.89.
Financials and valuation snapshot for MDAI stock
At close the market cap was $43.58M with 30,688,895 shares outstanding. Price sits below the 50-day average of $1.53 and below the 200-day average of $1.94, suggesting the stock trades under medium-term trend levels. Price-to-sales is 1.84, EV/sales is 1.81, and current ratio is 0.85, indicating tight short-term liquidity. Revenue per share TTM is 0.88, while free cash flow per share TTM is -0.17.
Technical view and trading flow for MDAI stock
Momentum is neutral with RSI at 50.34 and MACD near -0.06. The stock showed sharp intraday interest today with relative volume at 17.62, driving the 18.33% gain. Bollinger middle band is $1.38 and ATR is $0.10, so expect wider intraday swings into earnings. Short-term traders should note the large on‑balance-volume drop earlier, which can amplify volatility on news.
Meyka AI rates MDAI with a score out of 100 and forecast
Meyka AI rates MDAI with a score out of 100: 66.60 (Grade B) — HOLD. This grade factors in S&P 500 and sector comparisons, revenue growth, key metrics, forecast models, and analyst signals. Meyka AI’s forecast model projects $2.15 in 12 months for MDAI stock, implying 51.41% upside from the $1.42 close. Forecasts are model-based projections and not guarantees. These grades are not guaranteed and we are not financial advisors.
Risks and near-term catalysts for MDAI stock
Primary catalysts are FDA progress, BARDA milestones, and the upcoming earnings update on 24 Mar 2026. Key risks include continued cash burn, tight liquidity noted by a current ratio below 1.00, possible delays in FDA clearance, and concentration in wound-care applications. Positive trial results or commercialization pilots would be immediate upside triggers.
Final Thoughts
Spectral AI, Inc. (MDAI) enters earnings on 24 Mar 2026 with fresh momentum after a $31.70M BARDA award and a session close at $1.42 on NASDAQ. Trading volume of 7,175,859 shares versus an average of 402,294 shows the market is paying attention to government-backed development. Financially the company remains unprofitable with EPS TTM -0.75 and constrained liquidity, but the BARDA funding lowers near-term dilution risk and accelerates FDA work. Meyka AI’s forecast model projects $2.15 in 12 months, implying a 51.41% upside from the current price; this is a model projection and not a guarantee. For traders, watch the earnings commentary, FDA timeline updates, and any BARDA milestone language. For longer-term investors, the thesis depends on DeepView commercial adoption, reimbursement progress, and a path to sustainable free cash flow. See the latest filings and coverage for immediate updates at Meyka’s MDAI page and original sources below.
FAQs
When does Spectral AI report earnings and why it matters for MDAI stock
Spectral AI reports on 24 Mar 2026 after market close. The print matters because management may update FDA timing, BARDA milestones, revenue growth, and R&D spending, all of which can shift the near-term valuation of MDAI stock.
What is Meyka AI’s outlook for MDAI stock
Meyka AI projects $2.15 in 12 months for MDAI stock, implying 51.41% upside versus the $1.42 close. The forecast is model-based and not a guarantee; investors should weigh execution and FDA risk.
How did the BARDA award affect MDAI stock performance
The $31.70M BARDA award lifted MDAI stock sentiment and liquidity, driving an 18.33% intraday gain and volume of 7,175,859 shares, up from average volume 402,294. The funding reduces short-term dilution pressure.
What are the main risks investors should monitor in MDAI stock
Key risks for MDAI stock include FDA delays, continued negative EPS, tight liquidity with a current ratio of 0.85, and dependence on adoption of the DeepView system in a niche burn-care market.
Disclaimer:
Stock markets involve risks. This content is for informational purposes only. Past performance does not guarantee future results. Meyka AI PTY LTD provides market analysis and data insights, not financial advice. Always conduct your own research and consider consulting a licensed financial advisor.
What brings you to Meyka?
Pick what interests you most and we will get you started.
I'm here to read news
Find more articles like this one
I'm here to research stocks
Ask our AI about any stock
I'm here to track my Portfolio
Get daily updates and alerts (coming March 2026)